Please assess the completion status of the following clinical trial:

Trial Title: Effects of Denosumab on Bone Mineral Density in Women With Anorexia Nervosa: A Pilot Study

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion/Exclusion Criteria:~Inclusion Criteria:~* Female~* Age 20-60 years, skeletally mature with closed epiphyses~* Anorexia nervosa or atypical anorexia nervosa defined by DSM-V diagnostic criteria~* BMD T-score \< -1.0~* Normal serum 25-OH vitamin D (\>30 ng/mL) and calcium levels~* For women of reproductive age, agree to use an effective contraceptive method. Highly effective methods of birth control include:~  * Combined (estrogen and progestogen) hormonal methods (pills, vaginal ring, or skin patch)~ * Intrauterine device (IUD)~ * Intraduterine hormonal-releasing system (IUS)~ * Surgery to tie both fallopian tubes (bilateral tubal ligation/occlusion)~ * Your male partner has had a vasectomy and testing shows there is no sperm in the semen~* Dental check up within the past year~Exclusion Criteria:~* Any disease known to affect bone, including untreated thyroid dysfunction, Cushing's or renal failure~* Subjects with a known esophageal disease cannot participate in the alendronate extension study~* Any medication known to affect bone metabolism within 3 months of the study, excluding oral contraceptives or other forms of estrogen administration. Bisphosphonates must have been discontinued for at least one year before participation~* Immunodeficiency or taking immunosuppressive therapy~* Serum potassium \<3.0 meq/L~* Serum ALT \>3 times upper limit of normal~* eGFR of less than 30 ml/min~* Hypocalcemia~* Diabetes mellitus~* Active substance abuse, including alcohol~* History of malignancy~* Paget disease of bone~* Osteomalacia~* Osteonecrosis of the jaw (ONJ) or risk factor for ONJ, such as invasive dental procedures (eg, tooth extraction, dental implants, oral surgery in the past 6 months), poor oral hygiene, periodontal and/or pre-existing dental disease, and current use of corticosteroids.~* Planned invasive dental procedure over the next 24 months.~* Known senstivity to any of the products or components to be administered during dosing or known sensitivity to mammalian cell derived drug products~* Sensitivity to calcium or vitamin D supplements~* Pregnant, planning to become pregnant with 7 months after the end of treatment and/or breastfeeding

- Gender: FEMALE
- Minimum Age: 20 Years
- Maximum Age: 60 Years
- Healthy Volunteers: f

Study Arms:
- Active Denosumab 60mg Injection (Type: EXPERIMENTAL): Denosumab 60mg injection at baseline study visit and 6 month study visit. Alendronate 70mg PO weekly starting at Month 12 through 24 months.
- Placebo (Type: PLACEBO_COMPARATOR): Placebo injection at baseline study visit and 6 month study visit. Alendronate 70mg PO weekly starting at Month 12 through 24 months.

Based on this trial design, predict the completion outcome and termination type (if applicable).